Work

Defining “cisplatin ineligible” patients with metastatic bladder cancer.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.7_suppl.238

Authors: M. D. Galsky, N. M. Hahn, J. E. Rosenberg, G. Sonpavde, W. K. Oh, R. Dreicer, N. J. Vogelzang, C. N. Sternberg, D. F. Bajorin, J. Bellmunt, Cisplatin Ineligibility in Bladder Cancer Working Group

Institutions: Cleveland Clinic, Mount Sinai Health System, Memorial Sloan Kettering Cancer Center, Baylor College of Medicine, Dana-Farber Cancer Institute, Comprehensive Cancer Centers of Nevada, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Tisch Cancer Institute

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560282005

Cites:

Cited by: 27

Related to: 10